Wipfli Financial Advisors’s Pacific Biosciences PACB Stock Holding History

Wipfli Financial Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$4K	Buy	+643	New	+$3.69K	﹤0.01%	2151

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wipfli Financial Advisors's PACB Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Pacific Biosciences (PACB) in Q3 2022: 643 shares worth $4K. The stake represents ﹤0.01% of the portfolio and ranks #2151 among its holdings.

227 funds tracked by Wall St. Rank hold PACB as of Q3 2022.

Wipfli Financial Advisors held 643 shares of Pacific Biosciences worth $4K as of Q3 2022.
Pacific Biosciences was a new Wipfli Financial Advisors position in Q3 2022.
Pacific Biosciences made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2151 holding.
227 funds tracked by Wall St. Rank held Pacific Biosciences as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.